SYK-selective kinase inhibitor

oral, completed Ph. I in HV

from optimization of prior candidate

ACS Med. Chem. Lett. Feb. 12, 2020

Gilead Sciences, Seattle, WA

GS-9876 (lanraplenib)

GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: